Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $160.
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $160.